What are the precautions for Ebglyss (Lebrikizumab)?

In clinical studies of Ebglyss (Lebrikizumab) in the treatment of moderate to severe atopic dermatitis (AD), warnings and precautions such as allergies, conjunctivitis and keratitis, and parasitic infections have emerged. You should also pay attention to vaccination, discontinue the drug and resume it at a reduced dose after recovery, or permanently discontinue it according to the severity.

1. Allergy: Allergic reactions, including angioedema and urticaria, may occur when using Ebglyss. If a serious allergic reaction occurs, discontinue use of Ebglyss and initiate appropriate treatment.

2. Conjunctivitis and keratitis: Adverse reactions of conjunctivitis and keratitis have been reported in clinical trials. The incidence of conjunctivitis and keratitis was higher in subjects with atopic dermatitis who received Ebglyss compared to subjects who received placebo. Conjunctivitis is the most common eye disease. Most subjects with conjunctivitis or keratitis recover during treatment. Advise patients to report new or worsening eye symptoms to their physician.

3. Parasitic infections: Patients with known helminth infections were excluded from clinical studies. It is unclear whether Ebglyss affects the immune response to helminth infection by inhibiting IL-13 signaling. Treat patients with existing worm infections before starting treatment with Ebglyss. If a patient becomes infected while receiving Ebglyss treatment and does not respond to antihelmintic treatment, discontinue treatment until the infection resolves.

4. Vaccination: After injection of live vaccines, Ebglyss may change the patient's immunity and increase the risk of infection. Complete all age-appropriate vaccinations according to current immunization guidelines before receiving Ebglyss treatment. Avoid using live vaccines before or during treatment. There are no data on responses to live vaccines.